Equities research analysts expect Collegium Pharmaceutical Inc (NASDAQ:COLL) to post $49.73 million in sales for the current quarter, according to Zacks. Four analysts have provided estimates for Collegium Pharmaceutical’s earnings, with the highest sales estimate coming in at $67.67 million and the lowest estimate coming in at $24.50 million. Collegium Pharmaceutical posted sales of $2.17 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 2,191.7%. The business is expected to report its next quarterly earnings report on Wednesday, May 9th.
On average, analysts expect that Collegium Pharmaceutical will report full-year sales of $49.73 million for the current year, with estimates ranging from $227.20 million to $311.99 million. For the next fiscal year, analysts expect that the firm will post sales of $356.89 million per share, with estimates ranging from $315.73 million to $406.30 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Collegium Pharmaceutical.
Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Wednesday, March 7th. The specialty pharmaceutical company reported ($0.54) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.02. The firm had revenue of $10.79 million during the quarter, compared to analysts’ expectations of $9.88 million. Collegium Pharmaceutical had a negative return on equity of 73.00% and a negative net margin of 262.91%. Collegium Pharmaceutical’s quarterly revenue was up 728.4% compared to the same quarter last year.
Collegium Pharmaceutical stock opened at $26.54 on Friday. The firm has a market capitalization of $892.48, a price-to-earnings ratio of -10.62 and a beta of 0.81. Collegium Pharmaceutical has a fifty-two week low of $7.37 and a fifty-two week high of $29.90.
In other news, Chairman Michael Thomas Heffernan sold 20,000 shares of Collegium Pharmaceutical stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $25.01, for a total value of $500,200.00. Following the transaction, the chairman now owns 535,395 shares in the company, valued at approximately $13,390,228.95. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Alison B. Fleming sold 6,928 shares of Collegium Pharmaceutical stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $19.07, for a total value of $132,116.96. Following the completion of the transaction, the insider now owns 32,651 shares in the company, valued at approximately $622,654.57. The disclosure for this sale can be found here. In the last quarter, insiders sold 46,928 shares of company stock worth $1,082,317. Corporate insiders own 25.76% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the company. Benjamin F. Edwards & Company Inc. increased its stake in shares of Collegium Pharmaceutical by 87.5% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 7,500 shares of the specialty pharmaceutical company’s stock valued at $138,000 after purchasing an additional 3,500 shares during the last quarter. Acadian Asset Management LLC bought a new stake in Collegium Pharmaceutical during the 4th quarter worth $176,000. Monarch Partners Asset Management LLC bought a new stake in Collegium Pharmaceutical during the 4th quarter worth $264,000. Dimensional Fund Advisors LP bought a new stake in Collegium Pharmaceutical during the 2nd quarter worth $198,000. Finally, JPMorgan Chase & Co. bought a new stake in Collegium Pharmaceutical during the 3rd quarter worth $192,000. Institutional investors own 86.39% of the company’s stock.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.